UniQure rises as US FDA review talks revive hopes for Huntington's therapy

uniQure

09/01/2026 12:51

** U.S.-listed shares of Dutch firm UniQure UQ1.F, QURE.O rise 16% to $26.90 premarket

** Co says it has scheduled Type A meeting with U.S. FDA to discuss data for potential marketing application for AMT-130

** Co seeks accelerated approval for AMT-130, a gene therapy for Huntington's disease, which is a type of brain disorder with no approved treatments

** In September, trial data showed AMT‑130 slowed disease progression by 75%, sending QURE shares soaring more than threefold

** However, in November, health regulator said trial data may be inadequate to support marketing application, prompting shares to plunge

** UniQure climbed 32% in 2025

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))